Recombinant vaccinia virus derived from KVAC103 strain
US9879281B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 15, 2015 |
| Grant date | Jan 30, 2018 |
| Priority date | — |
| Expiry date | Nov 25, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/24143
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein is a novel recombinant virus vector derived from the attenuated vaccinia virus strain KVAC103. The recombinant virus vector is obtained by inserting an exogenous gene into the KVAC103 and may be used as a safe vaccine delivery vehicle in mammals. Particularly, recombinant viruses obtained by rescuing some of the genes deleted from the parent virus have an enhanced ability to proliferate in cells being cultured, and thus are easily produced. In addition, the recombinant viruses express an increased level of an exogenous antigen, and thus has enhanced immunogenic efficacy. Such recombinant virus vectors may be used in vaccines for preventing diseases, therapeutic vaccines, and molecular biological studies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.